肽受体放射性核素治疗联合化疗用于神经内分泌肿瘤患者
患者接受PRRT联合替莫唑胺(n=3)或替莫唑胺加卡培他滨(n=12)治疗。联合治疗后中位无进展生存期为7.1个月,中位总生存期为25.3个月;根据CT、[F]F-FDG PET/CT和[Ga]Ga-DOTATOC PET/CT评估的临床获益率分别为55%、38%和44%。
要点
- PRRT联合替莫唑胺±卡培他滨在经治进展NET中疾病控制率为38%–55%。
- 中位无进展生存期7.1个月,中位总生存期25.3个月。
- 多数患者未发生严重不良事件,但需关注肝毒性。
核心结论
- PRRT联合替莫唑胺±卡培他滨可使经PRRT或化疗单药治疗失败的进展性NET获得38%至55%的疾病控制,中位总生存期接近25个月,多数患者未发生严重不良事件。
研究设计与样本
- 患者接受PRRT联合替莫唑胺(n=3)或替莫唑胺加卡培他滨(n=12)治疗。
- 评估指标包括治疗反应、生存和不良事件。
主要发现
- 联合治疗3周期后[Lu]Lu-octreotate累积给药活度中位数为21.3 GBq。
- 中位无进展生存期为7.1个月,中位总生存期为25.3个月。
- 临床获益率(客观缓解加疾病稳定)按CT为55%,按[F]F-FDG PET/CT为38%,按[Ga]Ga-DOTATOC PET/CT为44%。
- 1例快速进展肝转移患者出现4级肝衰竭(CTCAE v5.0),另4例(27%)出现显著升高的3级肝脏参数。
关键数值与推荐
- 临床获益率按CT为55%,按[F]F-FDG PET/CT为38%,按[Ga]Ga-DOTATOC PET/CT为44%。
- 中位无进展生存期7.1个月,中位总生存期25.3个月。
- 联合治疗3周期后[Lu]Lu-octreotate累积给药活度中位数21.3 GBq。
临床怎么用
- 对于经化疗或PRRT单药治疗失败的快速进展G2/G3 NET患者,可考虑PRRT联合替莫唑胺±卡培他滨以争取疾病控制。
- 治疗期间应监测肝脏参数,警惕肝衰竭等严重不良事件。
局限性
- 来自2家德国癌症中心,可能存在选择偏倚。
- 联合化疗方案不一致(替莫唑胺单药3例,替莫唑胺加卡培他滨12例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies. METHODS: Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (n = 12). To evaluate the effects of the combined treatment, we assessed the responses, survival, and adverse events. RESULTS: The cumulative administered activity of [Lu]Lu-octreotate had a median of 21.3 GBq after 3 cycles of combination therapy. The patients exhibited a median progression-free survival of 7.1 months and a median overall survival of 25.3 months. The clinical benefit (objective response and stable disease) rates were as follows: 55% of patients according to CT, 38% in [F]F-FDG PET/CT, and 44% in [Ga]Ga-DOTATOC PET/CT. One patient with rapidly progressing liver metastases experienced grade 4 liver failure according to the Common Terminology Criteria for Adverse Events (version 5.0). Four other patients (27%) experienced significantly elevated (grade 3) liver parameters. CONCLUSIONS: According to different imaging modalities, the combination of PRRT and temozolomide +/- capecitabine led to disease control in 38% to 55% of the progressive NETs after PRRT or chemotherapy alone failed. The overall survival in this extensively pretreated group of patients was nearly 25 months. The majority of patients did not experience any serious adverse events.
引用
- Yordanova A, Ahrens H, Feldmann G, et al. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. Clin Nucl Med. 2019. PMID: 30932975. doi:10.1097/RLU.0000000000002532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。